| Literature DB >> 35893782 |
Yurena Luengo1, Zamira V Díaz-Riascos2,3,4, David García-Soriano1, Francisco J Teran1,5, Emilio J Artés-Ibáñez1, Oihane Ibarrola6, Álvaro Somoza1,5, Rodolfo Miranda1,5, Simó Schwartz2,4, Ibane Abasolo2,3,4, Gorka Salas1,5.
Abstract
The clinical implementation of magnetic hyperthermia has experienced little progress since the first clinical trial was completed in 2005. Some of the hurdles to overcome are the reliable production of magnetic nanoparticles with controlled properties and the control of the temperature at the target tissue in vivo. Here, forty samples of iron oxide superparamagnetic nanoparticles were prepared by similar methods and thoroughly characterized in terms of size, aggregation degree, and heating response. Selected samples were intratumorally administered in animals with subcutaneous xenografts of human pancreatic cancer. In vivo experiments showed that it is possible to control the rise in temperature by modulating the field intensity during in vivo magnetic hyperthermia protocols. The procedure does not require sophisticated materials and it can be easily implemented by researchers or practitioners working in magnetic hyperthermia therapies.Entities:
Keywords: cancer; controlled heat in vivo; magnetic hyperthermia; nanoparticles
Year: 2022 PMID: 35893782 PMCID: PMC9331462 DOI: 10.3390/pharmaceutics14081526
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525
Figure 1TEM micrographs and size distribution of different coprecipitation samples.
Labels used for each batch of nanoparticles before and after coating with dextran or starch.
| Uncoated Cores | Dextran Coating | Starch Coating |
|---|---|---|
| NP0 | NP0-D1 | - |
| NP1 | NP1-D1, NP1-D2, NP1-D3, NP1-D4, NP1-D5, NP1-D6, NP1-D7 | - |
| NP2 | NP2-D1, NP2-D2, NP2-D3, NP2-D4, NP2-D5, NP2-D6, NP2-D7 | NP2-S1, NP2-S2, NP2-S3 |
| NP3 | NP3-D1, NP3-D2, NP3-D3, NP3-D4, NP3-D5, NP3-D6, NP3-D7, NP3-D8 | NP3-S1, NP3-S2, NP3-S3, NP3-S4, NP3-S5, NP3-S6, NP3-S7, NP3-S8 |
| NP4 | NP4-D1, NP4-D2, NP4-D3, NP4-D4, NP4-D5, NP4-D6 | - |
Figure 2Thermogravimetric analysis (TGA) of NP3 samples coated with dextran (A) and starch (B). Hydrodynamic size distribution of NP3 samples coated with dextran (C) and starch (D). Each line corresponds to a single batch prepared under the same conditions.
Figure 3SAR values vs. hydrodynamic size measured at two different field conditions: (A) 300 kHz, 4 kA/m and (B) 100 kHz, 24 kA/m. Circles correspond to the dextran-coated samples and diamonds to the starch-coated samples (yellow for NP0, red for NP1, blue for NP2, green for NP3, and purple for NP4 batches). (C) SAR values vs. hydrodynamic size of nanoparticles with Dhyd < 155 nm and with PdI ≤ 0.15, measured at 300 kHz, 4 kA/m. The fit shows a linear decrease of SAR with Dhyd (slope = −0.09 W·g−1·nm−1, intercept = 15.9 W·g−1, R2 = 0.94).
Figure 4Heating abilities of NP0-D1 (red circles) and NP1-D6 (blue triangles) nanoparticles dispersed in water using the MACH system, keeping voltage fixed at 15 V (green line), corresponding to a field intensity of 4.5 kA/m. Results show that the nanoparticles increased the temperature of the media rapidly, even at the lowest voltage. Without nanoparticles, no temperature increase was detected (grey squares).
Figure 5In vivo optimization of heating protocols using the MACH system. (A) Mice bearing s.c. MIA PaCa-2 tumors were inoculated i.t. with NP2-D6 (1 mg Fe/100 mm3). (B) Twenty-four hours after administration, mice (n = 2 protocol) were exposed to AMF and body and tumor temperatures were recorded by two optical thermal probes. (C) AMF was applied using two different protocols: fast increase of voltage (left graph, fast protocol) or slow and steady increase in voltage (right graph, slow protocol). Graphs show one representative example of each procedure.
Figure 6Heating abilities and intratumoral distribution of NP0-D1 to NP4-D3 in s.c. pancreatic MIA PaCa-2 and BxPC3 tumors. Concentrations express the amount of nanoparticles (in mg of iron) per 100 mm3 of tumor volume. (A–D) NP1-D6 and NP4-D3, (E–H) NP0-D1 and NP3-D8. The variations with time of the recorded temperature at the tumor site (in blue), the rectal temperature (in orange), and the applied voltage (in green) are shown for the indicated samples (A,C–F,H). The grey dashed line represents the threshold of 40 °C. Intratumoral biodistribution of nanoparticles was imaged by CT for NP1-D6 and NP3-D8 (B and G, respectively). Only in tumors inoculated with NP0-D1 and NP3-D8 temperatures above 40 °C were recorded.